Review article · 2026 · Open access

Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report

Gilbert J. Burckart, Gelareh A. Abulwerdi, Christin L Daniels, Caleb Choi, Rebecca Racz, Jean‐Pierre Valentin, Kristin Ardlie, Nicholas P. Tatonetti, Susan B. Laffan, Marjory Moreau, Will Redfern, Lang Li and 5 more

Clinical Pharmacology & Therapeutics, 120(5), 1240–1249 · Published 2 October 2026 · DOI 10.1002/cpt.70493

Open PDFView at the publisherCite this paper

In brief

“Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report” is a 2026 review article by Gilbert J. Burckart and 16 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 2 citations as of 18 November 2026, which puts it in the top 6% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
2.14
References
47
Authors
17

Abstract

Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug-related effects may be delayed or manifested differently than in adults. Pharmacovigilance data, primarily from adults, is not always predictive of the response in children. Historically, juvenile animal studies have been used for nonclinical pediatric drug safety assessments exclusively, but the reduction in animal testing is a goal of public health agencies. To address this concern, the Office of Clinical Pharmacology at the U.S. FDA and the Triangle CERSI (Center of Excellence in Regulatory Science and Innovation) convened a workshop entitled: "Pediatric Developmental Safety Assessment and New Approach Methodologies (NAMs)," attended by experts from regulatory agencies, academia, and industry. Discussions focused on three overarching topics: (i) Secondary Pharmacology Screening Tools for Assessing Pediatric Developmental Safety; (ii) Non-clinical Tools for Pediatric Developmental Safety Assessment; and (iii) Computational and Data-Driven Tools for Pediatric Developmental Safety. These topics were examined within the framework of the S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals and E11A Pediatric Extrapolation guidances, which promote structured, question-based pediatric extrapolation in drug development and authorization. The workshop concluded that NAMs hold considerable promise to advance the assessment of pediatric drug developmental safety.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Burckart, G. J., Abulwerdi, G. A., Daniels, C. L., Choi, C., Racz, R., Valentin, J., Ardlie, K., Tatonetti, N. P., Laffan, S. B., Moreau, M., Redfern, W., Li, L., Hickman, J. J., Madabushi, R., Prasad, B., Yao, L. P., & Watkins, P. B. (2026). Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report. Clinical Pharmacology & Therapeutics, 120(5), 1240–1249. https://doi.org/10.1002/cpt.70493

MLA 9

Burckart, Gilbert J., et al. “Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report.” Clinical Pharmacology & Therapeutics, vol. 120, no. 5, 2026, pp. 1240–1249. https://doi.org/10.1002/cpt.70493.

Chicago

Burckart, Gilbert J., Gelareh A. Abulwerdi, Christin L Daniels, Caleb Choi, Rebecca Racz, Jean‐Pierre Valentin, Kristin Ardlie, et al. 2026. “Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report.” Clinical Pharmacology & Therapeutics 120 (5): 1240–1249. https://doi.org/10.1002/cpt.70493.

Harvard

Burckart, G. J. et al. (2026) ‘Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report’, Clinical Pharmacology & Therapeutics, 120(5), pp. 1240–1249. doi:10.1002/cpt.70493.

IEEE

G. J. Burckart et al., “Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report,” Clinical Pharmacology & Therapeutics, vol. 120, no. 5, pp. 1240–1249, 2026, doi: 10.1002/cpt.70493.

BibTeX

@article{burckart2026pediatric,
  title     = {{Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report}},
  author    = {Burckart, Gilbert J. and Abulwerdi, Gelareh A. and Daniels, Christin L and Choi, Caleb and Racz, Rebecca and Valentin, Jean‐Pierre and Ardlie, Kristin and Tatonetti, Nicholas P. and Laffan, Susan B. and Moreau, Marjory and Redfern, Will and Li, Lang and Hickman, James J. and Madabushi, Rajanikanth and Prasad, Bhagwat and Yao, Lynne P. and Watkins, Paul Brent},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  volume    = {120},
  number    = {5},
  pages     = {1240--1249},
  doi       = {10.1002/cpt.70493},
  url       = {https://doi.org/10.1002/cpt.70493}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices

  • drug safety in children
  • new approach methodologies
  • nonclinical safety assessment
  • computational tools
  • animal testing reduction
  • pediatric pharmacology

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Burckart, G. J., Abulwerdi, G. A., Daniels, C. L., Choi, C., Racz, R., Valentin, J., Ardlie, K., Tatonetti, N. P., Laffan, S. B., Moreau, M., Redfern, W., Li, L., Hickman, J. J., Madabushi, R., Prasad, B., Yao, L. P., & Watkins, P. B. (2026). Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report. Clinical Pharmacology & Therapeutics, 120(5), 1240–1249. https://doi.org/10.1002/cpt.70493

How many times has this paper been cited?

2 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Gilbert J. Burckart, Gelareh A. Abulwerdi, Christin L Daniels, Caleb Choi, Rebecca Racz, Jean‐Pierre Valentin, Kristin Ardlie, Nicholas P. Tatonetti, Susan B. Laffan, Marjory Moreau, Will Redfern, Lang Li and 5 more.

What is the DOI of this paper?

10.1002/cpt.70493, permanently at https://doi.org/10.1002/cpt.70493. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.